[Survival evaluation of children with acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munich trial].
OBJECTIVE
To determine the survival rate of children with acute lymphoblastic leukemia treated in Hospital São Lucas - Pontifícia Universidade Católica - Rio Grande do Sul during the past 10 years. To evaluate well known prognostic factors and to compare results of BFM 90 and 95 trials.


METHODS
Mixed cohort study of 0 to 15-years-old children treated with BFM 90 and 95 trials during the past 10 years at Hospital São Lucas - Pontifícia Universidade Católica - Rio Grande do Sul. Data were obtained from medical records. The occurrence of death was described by Kaplan-Meier survival curves. The overall effect of the prognostic factors was evaluated using the Cox's multivariate model.


RESULTS
Sixty three patients, whose mean age (+/- standard-deviation) was 6.3 +/- 4.2 years, were included. Thirty five patients (55.6%) were female. The estimated probability of relapse free survival at 5 years (+/- standard-error) was 50.8 +/- 7.2% for all patients, with 77.7 +/- 9.9% in the standard risk group, 41.3 +/- 15.4% in the intermediate risk group, and 39.3 +/- 13.7% in high risk group.


CONCLUSIONS
The estimated probability of relapse free survival was below the results in developed countries. However the standard risk group obtained better prognostic but the small number of the cases doesn't allow permanent conclusions.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013866:Thioguanine / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D013866:Thioguanine